Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / PCA3

PCA3

Basics

Aliases:
This biomarker is also known as:
  • NCRNA00019,
  • non-protein coding RNA 19,
  • PCAT3,
  • DD3,
  • prostate cancer antigen 3,
  • prostate cancer associated transcript 3 (non-protein coding),
  • prostate cancer antigen 3 (non-protein coding),

View in BioMuta

Description…

The prostate cancer antigen 3 (PCA3) gene is a highly specific biomarker upregulated in prostate cancer. Because there is no extensive open reading frame, the gene is thought to express a noncoding RNA. The FDA has approved an assay for prostate cancer that uses the ratio of PCA3 RNA to PSA RNA in urine. The assay is used to help physicians determine the need for repeat prostate biopsies in men 50 years of age or older who have had a previous negative biopsy. When used in conjunction with other clinical information, the use of this test can reduce the need for unnecessary prostate biopsies.

Attributes

QA State: Curated
Type: Gene
Short Name:
HGNC Name: PCA3

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Three
QA State: Curated

Overview

The prostate cancer antigen 3 (PCA3) gene is a highly specific biomarker upregulated in prostate cancer. The PCA3 gene (prostate cancer antigen 3) is a non-coding gene that is over-expressed in prostate cancer. PCA3 in conjunction with other clinical tools has been shown to be as effective as the PSA (prostate specific antigen) assay in predicting the presence of prostate cancer. The FDA recently approved the first molecular test that uses PCA3 to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

Performance Comment

The FDA has approved an assay for prostate cancer that uses the ratio of PCA3 RNA to PSA RNA in urine. The assay is used to help physicians determine the need for repeat prostate biopsies in men 50 years of age or older who have had a previous negative biopsy. When used in conjunction with other clinical information, the use of this test can reduce the need for unnecessary prostate biopsies.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.